Perpetual Ltd’s BridgeBio Pharma BBIO Stock Holding History

Perpetual Ltd’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	–	Sell	-8,583	Closed	-$639K	–	399
2026 Q2	$639K	Buy	+8,583	New	+$601K	0.01%	287

Other funds holding BBIO

Tema ETFs New York $2.69B AUM 42.96% 1-Year Est. Return

China Universal Asset Management Company Shanghai, China $1.92B AUM 74.14% 1-Year Est. Return

DekaBank Deutsche Girozentrale Frankfurt, Germany $87.8B AUM 20.94% 1-Year Est. Return

Vontobel Holding Zurich, Switzerland $27.7B AUM 21.75% 1-Year Est. Return

AssetMark Inc Concord, California $59.5B AUM 15.92% 1-Year Est. Return

Burney Company Reston, Virginia $3.66B AUM 27.59% 1-Year Est. Return

Oppenheimer Asset Management New York $9.5B AUM 23.46% 1-Year Est. Return

Y-Intercept (HK) Hong Kong $4.52B AUM 6.6% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

Amalgamated Bank New York $14.3B AUM 35.81% 1-Year Est. Return

Perpetual Ltd's BBIO Position: Q3 2026 in Review

Perpetual Ltd sold out of BridgeBio Pharma (BBIO) in Q3 2026, closing a stake of 8,583 shares — an estimated $639K sold.

Perpetual Ltd first reported a position in BBIO in Q2 2026 and held it in 1 quarter. The position peaked at $639K in Q2 2026. 86 funds tracked by Wall St. Rank hold BBIO as of Q3 2026.

Perpetual Ltd reported no remaining BridgeBio Pharma position as of Q3 2026 after selling out during the quarter.
Perpetual Ltd sold 8,583 BridgeBio Pharma shares in Q3 2026, an estimated $639K.
Perpetual Ltd first reported a position in BridgeBio Pharma in Q2 2026 and held it in 1 quarter.
Perpetual Ltd's BridgeBio Pharma position peaked at $639K in Q2 2026.
86 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q3 2026.

Based on Perpetual Ltd's 13F filing for Q3 2026, filed 13 Oct 2026.